The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Mimicking dominant negative inhibition of prion replication through structure-based drug design
Open accessAbstract
Recent progress determining the structure of the host-encoded prion protein (PrP C) and the role of auxiliary molecules in prion replication permits a more rational approach in the development of therapeutic interventions. Our objective is to identify a new class of lead compounds that mimic the dominant negative PrP C mutants, which inhibit an abnormal isoform (PrP Sc) formation. A computational search was conducted on the Available Chemicals Directory for molecules that mimic both the spatial orientation and basic polymorphism of PrP residues 168, 172, 215, and 219, which confer dominant negative inhibition. The search revealed 1,000 potential candidates that were visually analyzed with respect to the structure of this four-residue epitope on PrP C. Sixty-three compounds were tested for inhibition of PrP Sc formation in scrapie-infected mouse neuroblastoma cells (ScN2a). Two compounds, Cp-60 (2-amino-6-[(2-aminophenyl)thio]-4-(2-furyl)pyridine-3,5-dicarbonitrile) and Cp-62 (N′1-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-2-furyl}carbonyl)-4 methoxybenzene-1-sulfonohydrazide), inhibited PrP Sc formation in a dose-dependent manner and demonstrated low levels of toxicity. A substructure search of the Available Chemicals Directory based on Cp-60 identified five related molecules, three of which exhibited activities comparable to Cp-60. Mimicking dominant negative inhibition in the design of drugs that inhibit prion replication may provide a more general approach to developing therapeutics for deleterious protein–protein interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J., & Hill, A. F. (1996) · Nature · doi:10.1038/383685a0 · Cited by 1,735
Cited by
Neurodegenerative Diseases and Prions
Prusiner, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442006 · Cited by 772
Self-citationProtein aggregation diseases: pathogenicity and therapeutic perspectives
Aguzzi, A., & O'Connor, T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3050 · Cited by 762
Benign by design: catalyst-free in-water, on-water green chemical methodologies in organic synthesis
Gawande, M. B., Bonifácio, V. D. B., Luque, R., Branco, P. S., & Varma, R. S. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60025d · Cited by 674
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
Korth, C., May, B. C. H., Cohen, F. E., & Prusiner, S. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161274798 · Cited by 673
Self-citationAntibodies inhibit prion propagation and clear cell cultures of prion infectivity
Peretz, D., Williamson, R. A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulms, G., Mehlhorn, I. R., Legname, G., Wormald, M. R., Rudd, P. M., et al. (2001) · Nature · doi:10.1038/35089090 · Cited by 525
Self-citation
Metadata
- Authors
- Perrier, V., Wallace, A. C., Kaneko, K., Safar, J., Prusiner, S. B., & Cohen, F. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-05-23
- Volume
- 97
- Issue
- 11
- Pages
- 6073-6078
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2065489607
- Cited by
- 181
- References
- 2
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mimicking dominant negative inhibition of prion replication through structure-based drug design. https://app.cochat.ai/papers/10.1073/pnas.97.11.6073
- The paper
- Perrier, V., Wallace, A. C., Kaneko, K., Safar, J., Prusiner, S. B., & Cohen, F. E. (2000). Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.97.11.6073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.